Low glucose-6-phosphate dehydrogenase enzyme (G6PD) activity is a key determinant of
drug-induced haemolysis. More than 230 clinically relevant genetic variants have been …

Plasmodium vivax malaria continues to cause a significant burden of disease in the Asia-
Pacific, the Horn of Africa, and the Americas. In addition to schizontocidal treatment, the 8 …

Abstract Background Quantitative measurement of Glucose-6-Phosphate Dehydrogenase
(G6PD) enzyme activity is critical to decide on appropriate treatment and provision of radical …

In Cambodia, malaria cases are on a trajectory towards the goal of malaria elimination by
2025. Vivax malaria is difficult to eliminate because of hypnozoites that can cause relapse …

Background The 8-aminoquinoline antimalarials, the only drugs which prevent relapse of
vivax and ovale malaria (radical cure), cause dose-dependent oxidant haemolysis in …

Background: Glucose-6-phosphate dehydrogenase (G6PD) deficiency is an X-linked
hereditary disorder and a global public health concern that is most prevalent in malaria …

Background Glucose-6-Phosphate dehydrogenase (G6PD) deficiency is the most common
enzymopathy worldwide, no reliable bedside diagnostic tests to quantify G6PD activity exist …

Vivax malaria can relapse after an initial infection due to dormant liver stages of the parasite.
Radical cure can prevent relapses but requires the measurement of glucose-6-phosphate …

Introduction Glucose-6-phosphate dehydrogenase (G6PD) deficiency is the most common
enzymopathy in the human population affecting an estimated 8% of the world population …

Primaquine and tafenoquine are the only licensed drugs with activity against Plasmodium
vivax hypnozoites but cause haemolysis in patients with glucose–6–phosphate …